The study is a placebo controlled study, with two parallel arms, in which participants will
be randomly assigned in a 2:1 ratio to receive either active (200 mg safinamide) or placebo
in a double blind manner. Study population is patients diagnosed, with possible or probable
parkinsonian variant of Multiple System Atrophy who are on a stable treatment of levodopa